Loading
Reward companies that deliver a genuinely new kind of cancer drug with a sellable voucher for faster review of another product, but only if they agree to fair pricing and global access.
Extend the US priority review voucher model (rare paediatric disease, tropical disease) to oncology first-in-class approvals that show substantial survival benefit, with two conditions attached: a price commitment (for example launch price below a value-based threshold set by an independent body) and a global access plan (tiered pricing or licensing to the Medicines Patent Pool for low- and middle-income countries). The voucher is transferable and has sold for around $100 million historically, so the reward is real but costs the public little. Regulators would need statutory authority; a pilot could run through an existing programme's criteria.
Shares Patent term extension scaled to proven survival gain, Incentives reward me-too drugs and marginal gains, Prices and value.
Shares Breakthrough Therapy / Priority Review / Priority Voucher, Accelerated approval.
Shares Patent term extension scaled to proven survival gain, Incentives reward me-too drugs and marginal gains, Prices and value.
Shares Accelerated approval, Incentives reward me-too drugs and marginal gains.
Shares Patent term extension scaled to proven survival gain, Incentives reward me-too drugs and marginal gains.
Shares Patent term extension scaled to proven survival gain, Incentives reward me-too drugs and marginal gains.
Shares Accelerated approval, Incentives reward me-too drugs and marginal gains.
Shares Accelerated approval, Incentives reward me-too drugs and marginal gains.